<DOC>
	<DOCNO>NCT00749957</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy adeno-associated virus vector express RPE65 patient Leber congenital amaurosis cause mutation RPE65 gene . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Phase 1/2 Safety Efficacy Study AAV-RPE65 Vector Treat Leber Congenital Amaurosis</brief_title>
	<detailed_description>This non-randomized , open label study . A total 12 participant enrol two group 6 . Each participant receive rAAV2 CB hRPE65 subretinal injection one eye single occasion . Participants Group 1 receive 450 µL dosage level 4 x 10^11 vg/mL contain total 1.8 x 10^11 vg rAAV2-CB-hRPE65 . Participants Group 2 receive 450 µL dosage level 1.33 x 10^12 vg/mL contain total 6 x 10^11 vg rAAV2-CB-hRPE65 . A retinal surgeon administer vector subretinal injection . Enrollment begin Group 1 proceed Group 2 review safety data Data Safety Monitoring Committee . Safety monitor evaluation ocular non ocular adverse event hematology clinical chemistry parameter . Efficacy measure evaluation visual field , visual acuity electroretinography .</detailed_description>
	<mesh_term>Leber Congenital Amaurosis</mesh_term>
	<mesh_term>Blindness</mesh_term>
	<criteria>Retinal disease consistent diagnosis Leber congenital amaurosis document mutation RPE65 gene ( include null mutation mutation code abnormal RPE65 protein ) ; At least 6 year age ; Good general health without significant physical examination finding clinically significant abnormal laboratory result ; Able perform test visual retinal function ; Visual acuity well 20/60 bad hand motion treat eye fellow eye ; Visible photoreceptor ( out nuclear ) layer standard optical coherence tomography ( OCT ) scan ; Acceptable hematology , clinical chemistry urine laboratory parameter ; For female childbearing potential , negative pregnancy test screen baseline , agreement use effective contraception 12 month administration rAAV2CBhRPE65 , sexual activity could lead pregnancy ; For male reproductive potential , agreement use effective contraception 12 month administration rAAV2CBhRPE65 , sexual activity could lead pregnancy Preexisting eye condition would preclude plan surgery interfere interpretation study endpoint complication surgery ( e.g . glaucoma , corneal lenticular opacity , history retinal detachment ) ; Presence epiretinal membrane OCT ; History immunodeficiency medical condition might increase risk rAAV2CBhRPE65 administration ; Use anticoagulants antiplatelet agent within 7 day prior study agent administration ; History allergy sensitivity medication plan use perioperative period ; For female childbearing potential , positive pregnancy test screen baseline ( within 2 day rAAV2CBhRPE65 administration ) ; Females breast feeding ; Use investigational agent , systemic corticosteroid immunosuppressive drug ( ) , within 3 month prior enrollment ; Prior receipt AAV gene therapy product ; Any condition lead investigator believe participant comply protocol requirement may place participant unacceptable risk participation .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>AAV</keyword>
	<keyword>adeno-associated virus</keyword>
	<keyword>RPE65</keyword>
	<keyword>Leber congenital amaurosis</keyword>
	<keyword>LCA</keyword>
	<keyword>gene therapy</keyword>
	<keyword>human gene transfer</keyword>
</DOC>